Featured Posters & Presentations
Lyfgenia
Resolution of sickle cell disease manifestations in patients treated with lentiglobin gene therapy: Updated results from the Phase 1/2 HGB-206 Group C Study.
Authors: Kanter J.
Lyfgenia
Results from the completed HGB-205 trial of LentiGlobin for β-thalassemia and LentiGlobin for sickle cell disease gene therapy.
Authors: Magrin E.
Lyfgenia
The relationships between target gene transduction, engraftment of HSCs and RBC physiology in sickle cell disease gene therapy.
Authors: Bonner M.
Zynteglo
Long-term clinical outcomes of lentiglobin gene therapy for transfusion-dependent β-thalassemia in the Northstar (HGB-204) study.
Authors: Kwiatkowski JL.
Zynteglo
Northstar-2: Updated safety and efficacy analysis of lentiglobin gene therapy in patients with transfusion-dependent β-thalassemia and non-β0/β0 genotypes.
Authors: Thompson AA.
Zynteglo
Northstar-3: Interim results from a phase 3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent β-thalassemia and either a β0 or IVS-I-110 mutation at both alleles of the HBB gene.
Authors: Lal A.
Zynteglo
Routine management, healthcare resource use and patient/caregiver-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: a mixed methods observational study.
Authors: Shah F.